1. Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC
- Author
-
Benjamin Bachrach, Nawal M. Yessuf, Maria A. Velez, Paige M. Brodrick, Sarah R. Rettinger, Edward B. Garon, Philippe Rochigneux, Jackson P. Lind-Lebuffe, Jonathan W. Goldman, Aaron Lisberg, Jaklin Gukasyan, Debory Y. Li, Charlene M. Fares, Tristan Grogan, Wisdom O. Akingbemi, Nanruoyi Zhou, Amy L. Cummings, University of California [Los Angeles] (UCLA), University of California (UC), Providence Hlth & Serv, Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and ROCHIGNEUX, Philippe
- Subjects
Oncology ,Cancer Research ,Lung Neoplasms ,Anti-PD-(L)1 therapy ,endocrine system diseases ,[SDV]Life Sciences [q-bio] ,Thyroid Gland ,non-small cell lung cancer (NSCLC) ,Immune checkpoint inhibitor ,Non-small cell lung cancer ,Carcinoma, Non-Small-Cell Lung ,Non-Small-Cell Lung ,Lung ,Immune Checkpoint Inhibitors ,ComputingMilieux_MISCELLANEOUS ,Cancer ,Incidence (epidemiology) ,Lung Cancer ,Thyroid ,Thyroid dysfunction ,[SDV] Life Sciences [q-bio] ,medicine.anatomical_structure ,6.1 Pharmaceuticals ,Cohort ,hormones, hormone substitutes, and hormone antagonists ,Pulmonary and Respiratory Medicine ,endocrine system ,medicine.medical_specialty ,Clinical Sciences ,Oncology and Carcinogenesis ,Article ,Immune system ,Immune related adverse events ,Clinical Research ,Internal medicine ,medicine ,Humans ,Endocrine system ,Oncology & Carcinogenesis ,Adverse effect ,Retrospective Studies ,business.industry ,Carcinoma ,Evaluation of treatments and therapeutic interventions ,Retrospective cohort study ,medicine.disease ,Good Health and Well Being ,business - Abstract
Introduction Thyroid dysfunction is the most frequent endocrine immune related adverse event (irAE) in non-small cell lung cancer (NSCLC), typically arising 3–6 months into immune checkpoint inhibitor (ICI) therapy, but arising after ICI cessation, in some cases. Due to limited post-treatment adverse event reporting requirements on ICI trials, the incidence of ICI-induced thyroid dysfunction arising after therapy is unclear. We investigated ICI-induced thyroid dysfunction in a cohort of 294 NSCLC patients, with a specific focus on the post-treatment setting. Methods Retrospective analysis of ICI-induced thyroid dysfunction (clinically acted upon or laboratory only) was performed in 294 UCLA NSCLC patients treated 2012–2018. Clinically acted upon thyroid dysfunction was defined as thyroid diagnosis documentation and/or thyroid medication administration. Laboratory only dysfunction was defined as abnormal thyroid labs in the absence of clinical action. Timing of thyroid dysfunction relative to ICI treatment and thyroid monitoring patterns were also assessed. Results 82% (241/294) of ICI treated NSCLC patients had thyroid labs during treatment. Of these 241 patients, 13% (31/241) had clinically acted upon thyroid dysfunction prior to, 8% (18/241) during, and 4% (9/241) after ICI. Most patients, 66% (159/241), did not have thyroid labs after ICI, but in the 53 patients with labs and no prior clinical dysfunction, 17% (9/53) developed clinical dysfunction after ICI. In these 9 patients, median time from ICI initiation to dysfunction was 253 days. Two patients with post-treatment laboratory only dysfunction were observed. Conclusions ICI-induced thyroid dysfunction arising post-treatment appears more common than previously appreciated, warranting additional evaluation.
- Published
- 2021
- Full Text
- View/download PDF